Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
50 studies found for:    MK-2206
Show Display Options
Rank Status Study
1 Unknown  Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: MK2206
2 Completed
Has Results
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Condition: Colorectal Neoplasms
Intervention: Drug: MK-2206 + AZD6244
3 Terminated
Has Results
Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
Conditions: Colon Cancer;   Rectal Cancer
Intervention: Drug: MK-2206
4 Withdrawn Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: MK-2206;   Drug: Exemestane;   Drug: Goserelin
5 Completed
Has Results
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
Conditions: PANCREAS;   Neuroendocrine
Intervention: Drug: MK-2206
6 Withdrawn MK-2206 for Recurrent Malignant Glioma
Condition: Malignant Glioma
Intervention: Drug: MK-2206
7 Withdrawn MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: MSK-2206;   Drug: Exemestane;   Drug: Goserelin
8 Completed
Has Results
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: Ovarian Sarcoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis
9 Completed A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)
Condition: Solid Tumors
Interventions: Drug: MK2206 every other day;   Drug: MK2206 once weekly
10 Completed
Has Results
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
11 Active, not recruiting MK-2206 in Recurrent Nasopharyngeal Carcinoma
Condition: Recurrent Nasopharyngeal Carcinoma
Intervention: Drug: MK-2206
12 Active, not recruiting
Has Results
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
Conditions: Recurrent Oral Cavity Adenoid Cystic Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Oral Cavity Adenoid Cystic Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Oral Cavity Adenoid Cystic Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Oral Cavity Adenoid Cystic Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis
13 Completed A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
Condition: Locally Advanced or Metastatic Solid Tumors
Intervention: Drug: MK-2206 plus AZD6244
14 Completed
Has Results
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx
Intervention: Drug: Akt inhibitor MK2206
15 Active, not recruiting Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Conditions: Adult Solid Neoplasm;   Hormone-Resistant Prostate Cancer;   Recurrent Melanoma;   Recurrent Prostate Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Hydroxychloroquine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
16 Active, not recruiting Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Conditions: Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unresectable Pancreatic Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Dinaciclib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
17 Completed
Has Results
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
18 Active, not recruiting Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis
19 Terminated
Has Results
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
Conditions: Adult Hepatocellular Carcinoma;   Advanced Adult Hepatocellular Carcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Recurrent Adult Liver Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis
20 Active, not recruiting MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Conditions: Adult Solid Neoplasm;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.